AAAli Abbasi

Ali Abbasi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ali Abbasi has a total of 606 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of Methods and Attributes Used to Characterize Skin Quality: A Systematic Literature Review

    by Shannon Humphrey, David H. McDaniel, Patricia Ogilvie, Ali Abbasi, Stephanie Manson Brown, Tsing Cheng, Rahul Mehta, Sherket Peterson

    BACKGROUND: Skin quality is an aggregate term encompassing a broad range of skin attributes that convey its overall look, feel, and health. OBJECTIVE: To assess consistency in definitions and treatment outcomes for various skin quality attributes. MATERIALS AND METHODS: We searched PubMed, MEDLINE, and Embase to perform 2 systematic reviews. The initial search identified published articles (January 1, 2000–October 13, 2021) and abstracts (January 1, 2019–October 13, 2021) that used an objective or subjective instrument to assess skin quality at ≥2 timepoints. A supplemental search of meta-analyses published from 2010 to May 2024 was conducted to evaluate treatment outcomes for each skin quality attribute. RESULTS: The initial search included 903 studies comprising 4,668 individual observations. Subjective end points comprised 87% of observations. Substantial inconsistencies were identified in the definition of individual skin quality attributes across studies, with multiple definitions in use in the literature for each attribute (range, 7–17) and no clear consensus. CONCLUSION: This extensive review of the current state of the aesthetic medicine literature revealed an absence of consensus definitions for skin quality attributes, which poses a barrier to comparative evaluation of treatment options and could affect physician recommendations, potentially with downstream effects on patient outcomes.


  • Open Access

    Epidemiology and 10-year clinical care of juvenile myasthenia gravis in England: a retrospective cohort study

    by Ali Abbasi, Kerina Bonar, Piotr Zaremba, Anna Scowcroft, Sigrid Nilius, Frank Tennigkeit, Saiju Jacob, Sithara Ramdas

    Background: Published evidence is limited on the clinical burden of juvenile myasthenia gravis (JMG). We aimed to assess epidemiology and the clinical characteristics of JMG in England. Methods: We performed a retrospective analysis of patients with newly diagnosed JMG identified in England via primary care and hospital data between 2010 and 2019. Results: 32 children (aged 2–17 years) with newly diagnosed JMG were included. Prevalence of JMG ranged from 2.2 (95% CI 1.5 to 3.1) in 2012 to 2.5 (95% CI 1.8 to 3.4) per 100 000 in 2018. The annual incidence ranged from 0.8 (95% CI 0.1 to 5.7) in 2015 to 3.8 (95% CI 1.6 to 9.0) per million per year in 2017. Incidence fluctuated in females from 1.6 (95% CI 0.2 to 11.3) in 2016 to 6 (95% CI 2.3 to 16.1) per million per year in 2018. Overall, 20 patients received first acetylcholinesterase inhibitors or corticosteroids with no prior therapy during the study period. During the follow-up period (median, 3.3 years), 17 patients (53.1%) with JMG experienced a hospitalisation. No deaths were observed. Conclusions: This study confirms the rarity of JMG in England, with steady incidence and prevalence rates over a decade. Further research is required to assess unmet needs in JMG therapy and the importance of effective treatments for this condition.


  • Using an expanded algorithm to estimate prevalence of amyotrophic lateral sclerosis in U.S. and UK

    by Ali Abbasi, Henrik Fryk, Jan Rudnik, Richard White, Mark Vanderkelen, Anna Scowcroft, Kerina Bonar

    Background There is an increasing need to better understand the burden of amyotrophic lateral sclerosis (ALS) using real-world data (RWD). However, identifying ALS cases using RWD presents several challenges due to the rarity of ALS and the differences in database coding systems. Methods MarketScan claims, and the UK Clinical Practice Research Datalink (CPRD) databases were searched for diagnosis codes of ALS or MND, the only drugs approved for treating ALS (riluzole and edaravone) and clinical visits with 12-month enrolment prior to 1 January 2011. The main algorithm required ≥ 1 ALS diagnosis code together with prescriptions or clinical visits. We expanded the existing algorithm to identify unspecific (possible) ALS group that had codes for motor neuron disease (MND) and the ALS drugs. The study period was from 1 January 2011 until 31 December 2020. Results We identified 16,246 patients with ≥ 1 ALS code in Marketscan (denominator n = 85,279,619), yet only 184 were found in the UK CPRD (denominator n = 21,318,589). Using the main algorithm 9,433 ALS patients were included in MarketScan, with a prevalence ranged between 4.5 per 100,000 in 2019 and 6.2 in 2015. In MarketScan, 3,658 (4.3 per 100,000) had ≥ 1 MND code and the ALS drug codes (possible cases). In CPRD, 47.9% of 2,785 patients with ≥ 1 MND code had a prescription for riluzole (6.3 per 100,000), regarded as possible ALS cases. Conclusions The expanded algorithm enabled the identification of a large population with ALS, or possible ALS, and the estimation of ALS prevalence in MarketScan and CPRD.


  • Correction to: Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study

    by A. Abbasi, E. Corpeleijn, E. Meijer, D. Postmus, R. T. Gansevoort, R. O. B. Gans, J. Struck, H. L. Hillege, R. P. Stolk, G. Navis, et al.

    The values given for copeptin levels in men in quartiles 1 and 2 (Table 1) were incorrect, and should have read.


  • Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders

    by Symen Ligthart, Ahmad Vaez, Urmo Võsa, Maria G. Stathopoulou, Paul S. de Vries, Bram P. Prins, Peter J. Van der Most, Toshiko Tanaka, Elnaz Naderi, Lynda M. Rose, et al.


  • Open Access

    Blood Eosinophil Count and Metabolic, Cardiac and Pulmonary Outcomes: A Mendelian Randomization Study

    by Marzyeh Amini, Judith M. Vonk, Ali Abbasi, Bram P. Prins, Marcel Bruinenberg, Lude Franke, Pim van der Harst, Gerjan Navis, Gerard H. Koppelman, Bruce H. R. Wolffenbuttel, et al.

    Blood eosinophil count is associated with a variety of common complex outcomes in epidemiological observation. The aim of this study was to explore the causal association between determined blood eosinophil count and 20 common complex outcomes (10 metabolic, 6 cardiac, and 4 pulmonary). Through Mendelian randomization, we investigated genetic evidence for the genetically determined eosinophil in association with each outcomes using individual-level LifeLines cohort data (n = 13,301), where a weighted eosinophil genetic risk score comprising five eosinophil associated variants was created. We further examined the associations of the genetically determined eosinophil with those outcomes using summary statistics obtained from genome-wide association study consortia (6 consortia and 14 outcomes). Blood eosinophil count, by a 1-SD genetically increased, was not statistically associated with common complex outcomes in the LifeLines. Using the summary statistics, we showed that a higher genetically determined eosinophil count had a significant association with lower odds of obesity (odds ratio (OR) 0.81, 95% confidence interval (CI) [0.74, 0.89]) but not with the other traits and diseases. To conclude, an elevated eosinophil count is unlikely to be causally associated to higher risk of metabolic, cardiac, and pulmonary outcomes. Further studies with a stronger genetic risk score for eosinophil count may support these results.


  • Urine albumin excretion and the risk of incident atrial fibrillation: predictive or aetiological relevance?

    by Ali Abbasi

    I read with great interest the article by Marcos et al. investigating observational associations of urine albumin measures either by a simple urine albumin test or a more complex 24-h urine collection test with incident atrial fibrillation (AF) in an apparently healthy general population cohort enriched with individuals having an urine albumin concentration >10 mg/L at baseline.1 In line with previously published epidemiological studies, the authors report a positive association between elevated urine albumin and an increased risk of incident AF. While the associations were independent of common and novel risk factors in prospective observations, but a possibility of unmeasured confounding or reverse causality cannot be ruled out. As the authors and others noted a complementary strand of evidence from a randomized clinical trial or its analog, called...

  • Comment on Muka et al. Associations of Steroid Sex Hormones and Sex Hormone–Binding Globulin With the Risk of Type 2 Diabetes in Women: A Population-Based Cohort Study and Meta-analysis. Diabetes 2017;66:577–586

    by Ali Abbasi

    In the March 2017 issue of Diabetes , Muka et al. (1) report observational evidence for the associations of endogenous steroid sex hormones (including testosterone and estradiol) and sex hormone–binding globulin with the risk of type 2 diabetes in women. They used individual-level data (from the Rotterdam Study in the Netherlands) and also performed a meta-analysis of previous epidemiological observations including up to 1,912 incident cases (1). While the authors have meticulously taken …


  • Open Access

    Mendelian randomization for investigating causal roles of biomarkers in multifactorial health outcomes: a lesson from studies on liver biomarkers

    by Ali Abbasi

    Mendelian randomization that uses genetic variants as instrumental variables (IVs) is an example of the acquisition of cross-disciplinary analysis. Whereas methods for IV analysis in econometrics or for control of confounding in non-randomized studies were proposed several decades ago,1 formal applications of Mendelian randomization were considered in early 2000s.1 A simple search term (‘Mendelian randomization’ or ‘Mendelian randomisation’) in Medline PubMed shows 911 titles that are mainly investigating causal roles of a wide range of exposures (e.g. a certain biomarker) in multifactorial health outcomes. The most recent application of Mendelian randomization is to validate drug targets or investigate the performance (efficacy and safety) profiling of such targets in clinical trials.2,3